ReviewTherapeutics and clinical risk management2016

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib.

Sacha I RothschildPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.